Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:36:33.073Z.
Calculation as of: 2026-10-06T19:36:33.073Z.
Quote observation: 2026-10-06T19:35:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fb444e1e26cbd5896b6e324764cb09ba059118d447e0aa37aaedcb3e28ce7b2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$6.65M
EV/EBIT Ratio
N/A
TTM Avg
1748.82x
3Y Avg
1748.82x
5Y Avg
1748.82x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.72M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.65M | N/A | 1748.82x | 1748.82x | 1748.82x |
| Aclarion, Inc. (ACON)vs › | $6.60M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.87M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.54M | N/A | 471.11x | 281.60x | 221.14x |
| Co-Diagnostics, Inc. (CODX)vs › | $6.97M | N/A | 1.45x | 7.74x | 7.74x |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.95M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.00M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
